The July 2026 FDA Pharmacy Compounding Advisory Committee vote of 8-6 (one abstention) recommending BPC-157 free base and acetate for the 503A Bulk Drug Substances List represents the key recent catalyst for trader positioning on timelines for Category 1 status. This non-binding advisory outcome followed the peptide’s April 2026 removal from Category 2 restrictions and ran counter to FDA staff briefing documents that highlighted limited human data, route-specific evidence gaps, and characterization concerns. Full movement to the bulks list, which would authorize compounding under prescription, requires subsequent FDA rulemaking with notice-and-comment periods that historically span many months. As of early October 2026, no proposed rule or final agency action has been issued, leaving BPC-157 in regulatory limbo despite the committee signal. Traders therefore weigh the advisory vote’s momentum against procedural delays, the agency’s discretion not to follow recommendations, and parallel reviews for similar peptides when assessing resolution probabilities by specific deadlines.